β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

Item

http://www.wikidata.org/entity/Q36644786

Q36644786

about

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections An update on the management of urinary tract infections in the era of antimicrobial resistance.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resis Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2.

P2860

Q28069563-1DA5175C-6645-4697-A71A-C4F6D53CA10E Q30244815-360E0327-D92F-4190-AF79-54DE2662E8DA Q38797485-3F21DEA9-8A73-4281-A3BD-6B597656300D Q40276518-8239860C-966D-4073-BD01-90E8F14410ED Q48208212-4150C995-E2D5-411B-8D71-3817CF74CC95

P2860

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

Item

http://www.wikidata.org/entity/Q36644786

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

β-Lactamase Characterization o ...... ularly Characterized Isolates.

@ast

β-Lactamase Characterization o ...... ularly Characterized Isolates.

@en

type

Item

label

β-Lactamase Characterization o ...... ularly Characterized Isolates.

@ast

β-Lactamase Characterization o ...... ularly Characterized Isolates.

@en

prefLabel

β-Lactamase Characterization o ...... ularly Characterized Isolates.

@ast

β-Lactamase Characterization o ...... ularly Characterized Isolates.

@en

P1476

β-Lactamase Characterization o ...... ularly Characterized Isolates.

@en

P2093

Gregory G Stone

http://www.w3.org/2001/XMLSchema#string

Leanne Gasink

http://www.w3.org/2001/XMLSchema#string

Rodrigo E Mendes

http://www.w3.org/2001/XMLSchema#string

Ronald N Jones

http://www.w3.org/2001/XMLSchema#string

Wright W Nichols

http://www.w3.org/2001/XMLSchema#string

P2860

A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131

Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding

Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.

Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study

Extended-spectrum beta-lactamase-positive Escherichia coli causing complicated upper urinary tract infection: Urologist should act in time.

New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality.

Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases,

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community.

P304

1328-1335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01173-15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mariana Castanheira

Robert K Flamm

P577

2015-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26666936

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

Gram-negative bacteria

P932

4775982

http://www.w3.org/2001/XMLSchema#string

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

about

P2860

P2860

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932